Cost and access problems are pushing many Americans to change how they take GLP-1 drugs, or to buy unapproved versions. This guide sets out what that involves, what the risks are, and what safer options exist.
What are GLP-1 drugs and what are they prescribed for?
GLP-1 receptor agonists are medicines that copy the action of a gut hormone called glucagon-like peptide-1. This hormone helps control blood sugar and appetite. Semaglutide was first approved to treat type 2 diabetes, and is also licensed for weight management. Tirzepatide acts on GLP-1 and a second hormone pathway. Most of these drugs come as weekly injections, usually from a pre-filled pen, though some oral forms exist. A prescriber normally begins with a low dose and raises it step by step. Each step gives the body time to adjust and reduces side effects such as nausea, vomiting and constipation. The intended dose, the schedule and how quickly the dose goes up are all set out in the product’s approved labelling.
What does “not taking them as prescribed” actually mean?
Ars Technica reports that millions of people in the US are using GLP-1 drugs in ways that differ from their approved use, and that many are using versions that are not approved at all. In practice this covers several things. Some people take smaller doses than prescribed, or space injections further apart, so that an expensive supply lasts longer. Some take very small “microdoses” for reasons that have not been formally studied. Others stay on a starter dose indefinitely rather than moving up. And some buy compounded or unlicensed products instead of the branded medicine. The source does not provide a precise breakdown of how many people fall into each group, and that figure is not known here.
Why are cost and access such a barrier?
Ars Technica identifies cost and access as the main forces behind this behaviour. Branded GLP-1 drugs have high list prices in the US. Insurance cover is uneven, particularly when the drug is prescribed for weight loss rather than diabetes. Some health plans exclude weight-management drugs altogether. Others require prior authorisation or proof that cheaper treatments have been tried first. Where a patient pays the full price, a monthly supply can be beyond their budget. Supply has also been a problem at times, with pharmacies unable to fill some doses. When the approved route is too expensive or unreliable, people look for workarounds. These include rationing their own supply or turning to sellers who offer lower prices.
What are unapproved or compounded GLP-1s?
Compounding is when a licensed pharmacy prepares a medicine for an individual patient, often because no approved product suits that person. Compounded GLP-1 products are made with the same active ingredient as the branded drug. However, they have not been through the regulator’s approval process for that specific formulation. Some contain added ingredients, or use salt forms of the molecule that differ from the approved version. Beyond legitimate compounding pharmacies, there is a wider grey and black market. This includes websites selling “research peptides” labelled not for human use, and products of unknown origin sold through social media. Each of these sits on a different rung of regulatory oversight, and the risks increase as oversight decreases.
What are the risks of products bought outside regulated channels?
The main concern is that the buyer cannot confirm what is in the vial. An unregulated product may contain more or less of the active ingredient than stated, the wrong substance entirely, or contaminants. Sterility matters for any injectable: a contaminated product can cause infections. Compounded and research products are often supplied in multi-dose vials rather than pre-filled pens. That means the user must draw up a dose with a syringe and convert milligrams into units, which creates room for measuring errors. Products bought online may have been stored at the wrong temperature. If something goes wrong, there may be no reliable batch information to report and no clear party responsible. Approved medicines carry these risks to a far smaller degree.
Is it safe to stretch doses or take smaller amounts?
There is little formal evidence on taking lower or less frequent doses than the approved schedule, so how well this works and how safe it is are largely unknown. A smaller dose may give a weaker effect on blood sugar or appetite. For someone with type 2 diabetes, taking less than prescribed could leave their glucose poorly controlled. That carries its own health risks. Splitting doses from a pen that was not designed for it can also give inaccurate amounts. Skipping doses for too long and then restarting at a high dose may bring back strong gastrointestinal side effects. Any change to dose or timing is best agreed with a prescriber, who can adjust the plan safely and monitor the results.
What happens if you stop or pause a GLP-1?
GLP-1 drugs work while they are being taken. Their effects on appetite and blood sugar tend to fade after they are stopped. People using them for weight management often find appetite returns, and weight that was lost may come back gradually. For people with diabetes, stopping without another treatment in place can cause blood sugar to rise. Pausing because of cost or shortages is common, but restarting is not always as simple as taking the last dose again. A prescriber may advise going back to a lower step and building up again to limit side effects. How quickly effects wear off varies from person to person. That is one reason a planned approach is safer than an abrupt stop.
How can you check whether a supplier is legitimate?
A legitimate supplier will require a valid prescription from a licensed clinician. Be wary of any seller that offers GLP-1 drugs without one. In the US, pharmacies are licensed at state level, and state boards of pharmacy keep public lists of licensed premises. Industry accreditation schemes for online pharmacies can also help. Warning signs include products labelled “for research use only”, prices far below normal market rates, payment only through unusual methods, and no physical address or pharmacist contact. A pharmacy should be able to explain where its active ingredient comes from and how the product was made. If a telehealth service sends compounded medicine, it is reasonable to ask which pharmacy prepared it and how that pharmacy is regulated.
What practical steps can lower the cost legitimately?
Several routes are worth checking before turning to unregulated sources. Patients with insurance can ask their plan exactly what is covered and whether an appeal or prior authorisation request could succeed. Manufacturers run savings card schemes and patient assistance programmes. Eligibility varies, and these often exclude people on government insurance. Some manufacturers sell certain products directly to patients at a lower cash price. Prices also differ between pharmacies, so comparing quotes can help. A prescriber may be able to suggest a different approved GLP-1 that is covered, or another treatment altogether. Current terms for these programmes change regularly, so the details should be confirmed directly with the insurer, manufacturer or pharmacy.
What should you discuss with your prescriber?
Be open about cost. A clinician cannot help with a barrier they do not know about, and many are used to the problem. Tell them if you have been skipping or reducing doses, or using a compounded or online product, so they can judge your treatment accurately. Ask whether a lower maintenance dose would be suitable for you, rather than adjusting it yourself. Ask what to do if a dose is unavailable, and how to restart safely after a gap. People with diabetes should ask how to monitor their blood sugar during any change. If you have side effects from any product, report them to your prescriber. Reporting can also go through the national system for adverse events.
Sources and further reading
- Ars Technica: reporting on unapproved GLP-1 products and off-label use patterns in the US
- US Food and Drug Administration: guidance on compounded medicines and approved GLP-1 labelling
- State boards of pharmacy: public directories for checking pharmacy licences
- Manufacturer prescribing information: approved dosing schedules and safety information for GLP-1 medicines
Surfaced from the rss:arstechnica signal “GLP-1 off-label use”. AI-assisted draft, editorially reviewed.
